Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells

Molecular Vision

Volumn 16, Issue , 2010, Pages 246-251

  Lee, Kelvin Yoon Chiang ^a,b   Nakayama, Mao ^a   Aihara, Makoto ^a   Chen, Yi Ning ^a   Araie, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; BRIMONIDINE; GLUTAMIC ACID; YOHIMBINE; NEUROPROTECTIVE AGENT; QUINOXALINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HYPOXIA; IN VITRO STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; WISTAR RAT; ANIMAL; CELL HYPOXIA; CELL SEPARATION; DRUG EFFECT; PATHOLOGY; TOXICITY AND INTOXICATION;

ANIMALS; CELL HYPOXIA; CELL SEPARATION; CELL SURVIVAL; GLUTAMIC ACID; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; OXIDATIVE STRESS; QUINOXALINES; RATS; RATS, WISTAR; RETINAL GANGLION CELLS;

EID: 77952310360     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82:844-851. [PMID: 15640920]
2. Castagne V, Gautschi M, Lefevre K, Posada A, Clarke PG. Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system. Prog Neurobiol 1999; 59:397-423. [PMID: 10501635]
3. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001; 20:319-349. [PMID: 11286896]
4. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 2000; 41:4169-4174. [PMID: 11095611]
5. Lipton SA. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res 2001; 131:712-718. [PMID: 11420983]
6. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18:39-57. [PMID: 9920498]
7. Seki M, Lipton SA. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog Brain Res 2008; 173:495-510. [PMID: 18929130]
8. Wax MB, Tezel G. Neurobiology of glaucomatous optic neuropathy: diverse cellular events in neurodegeneration and neuroprotection. Mol Neurobiol 2002; 26:45-55. [PMID: 12392055]
9. Cantor LB, Burke J. Brimonidine. Expert Opin Investig Drugs 1997; 6:1063-1083. [PMID: 15989664]
10. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113:1514-1517. [PMID: 7487618]
11. Wilensky JT. The role of brimonidine in the treatment of openangle glaucoma. Surv Ophthalmol 1996; 41:S3-S7. [PMID: 8970244]
12. Adkins JC, Balfour JA. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 1998; 12:225-241. [PMID: 9534022]
13. David R. Brimonidine (Alphagan): a clinical profile four years after launch. Eur J Ophthalmol 2001; 11:S72-S77. [PMID: 11592536]
14. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res 2001; 913:133-139. [PMID: 11549376]
15. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Chauhan BC, Tremblay F, Kelly MEM. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci 2002; 43:2666-2676. [PMID: 12147601]
16. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42:2849-2855. [PMID: 11687528]
17. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 1999; 40:65-73. [PMID: 9888428]
18. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005; 112:376-385. [PMID: 15745762]
19. Chen YN, Yamada H, Mao W, Matsuyama S, Aihara M, Araie M. Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists. Brain Res 2007; 1148:28-37. [PMID: 17368577]
20. Yamada H, Chen YN, Aihara M, Araie M. Neuroprotective effect of calcium channel blocker against retinal ganglion cell damage under hypoxia. Brain Res 2006; 1071:75-80. [PMID: 16413513]
21. Yu ZK, Chen YN, Aihara M, Mao W, Uchida S, Araie M. Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells. Mol Vis 2007; 13:833-839. [PMID: 17615544]
22. Neal MJ, Cunningham JR, Hutson PH, Hogg J. Effects of ischaemia on neurotransmitter release from the isolated retina. J Neurochem 1994; 62:1025-1033. [PMID: 7906713]
23. Ohia SE, Awe OS, Opere CA, LeDay AM, Harris LC, Sharif NA. Hypoxia-induced [(3)H]D-aspartate release from isolated bovine retina: modulation by calcium-channel blockers and glutamatergic agonists and antagonists. Curr Eye Res 2001; 23:386-392. [PMID: 11910529]
24. Rego AC, Santos MS, Oliveira CR. Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J Neurochem 1996; 66:2506-2516. [PMID: 8632176]
25. Tezel G, Wax MB. Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci 1999; 40:2660-2667. [PMID: 10509663]
26. Vorwerk CK, Naskar R, Schuettauf F, Quinto K, Zurakowski D, Gochenauer G, Robinson MB, Mackler SA, Dreyer EB. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci 2000; 41:3615-3621. [PMID: 11006260]
27. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci 1988; 11:465-469. [PMID: 2469166]
28. Organisciak DT, Darrow RM, Barsalou L, Darrow RA, Kutty RK, Kutty G, Wiggert B. Light history and age-related changes in retinal light damage. Invest Ophthalmol Vis Sci 1998; 39:1107-1116. [PMID: 9620069]
29. Orrenius S, Burkitt MJ, Kass GE, Dypbukt JM, Nicotera P. Calcium ions and oxidative cell injury. Ann Neurol 1992; 32:S33-S42. [PMID: 1510379]
30. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Mol Vis 1999; 5:32. [PMID: 10562656]
31. Kawasaki A, Otori Y, Barnstable CJ. Muller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. Invest Ophthalmol Vis Sci 2000; 41:3444-3450. [PMID: 11006237]
32. Otori Y, Wei JY, Barnstable CJ. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest Ophthalmol Vis Sci 1998; 39:972-981. [PMID: 9579476]
33. Brewer GJ, Torricelli JR, Evege EK, Price PJ. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 1993; 35:567-576. [PMID: 8377226]
34. Perry SW, Norman JP, Litzburg A, Gelbard HA. Antioxidants are required during the early critical period, but not later, for neuronal survival. J Neurosci Res 2004; 78:485-492. [PMID: 15389829]
35. Chung HS, Harris A, Evans DW, Kagemann L, Garzozi HJ, Martin B. Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43:S43-S50. [PMID: 10416746]
36. Costa VP, Harris A, Stefánsson E, Flammer J, Krieglstein GK, Orzalesi N, Heijl A, Renard JP, Serra LM. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res 2003; 22:769-805. [PMID: 14575724]
37. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol 1994; 38:S3-S6. [PMID: 7940146]
38. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2- adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16:5986-5992. [PMID: 8815881]
39. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001; 296:216-223. [PMID: 11123383]
40. Dong CJ, Guo Y, Wheeler L, Hare WA. Alpha2 adrenergic receptor-mediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina. Invest Ophthalmol Vis Sci 2007; 48:1410-1415. [PMID: 17325190]
41. Zarbin MA, Wamsley JK, Palacios JM, Kuhar MJ. Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina. Brain Res 1986; 374:75-92. [PMID: 3013364]
42. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 2001; 11:S30-S35. [PMID: 11592528]
43. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol 2005; 89:758-763. [PMID: 15923515]
44. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res 1992; 24:213-219. [PMID: 1359487]
45. Woldemussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Vis Neurosci 2007; 24:745-756. [PMID: 17986363]
46. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49:4515-4522. [PMID: 18566471]
47. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999; 9:S17-S21. [PMID: 10230601]
48. Tatton WG, Chalmers-Redman RM, Tatton NA. Apoptosis and anti-apoptosis signalling in glaucomatous retinopathy. Eur J Ophthalmol 2001; 11:S12-S22. [PMID: 11592526]
49. Gao H, Qiao X, Cantor LB. WuDunn D. Up-regulation of brainderived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120:797-803. [PMID: 12049586]
50. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 2002; 30:421-429. [PMID: 11901096]
51. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001; 108:784-787. [PMID: 11297498]
52. Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidine-purite 0.15%. J Ocul Pharmacol Ther 2006; 22:242-246. [PMID: 16910864]